$0.76 EPS Expected for Maximus, Inc. (NYSE:MMS) This Quarter
Analysts expect that Maximus, Inc. (NYSE:MMS) will announce $0.76 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Maximus’ earnings, with the highest EPS estimate coming in at $0.78 and the lowest estimate coming in at $0.75. Maximus reported earnings of $0.77 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.3%. The firm is expected to announce its next earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Maximus will report full-year earnings of $3.13 per share for the current year, with EPS estimates ranging from $3.12 to $3.14. For the next financial year, analysts anticipate that the business will report earnings of $3.22 per share, with EPS estimates ranging from $3.15 to $3.30. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Maximus.
Maximus (NYSE:MMS) last issued its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million for the quarter, compared to the consensus estimate of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. Maximus’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.79 EPS.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Maximus from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a report on Saturday. Maxim Group set a $66.00 target price on shares of Maximus and gave the stock a “hold” rating in a report on Thursday, August 3rd. BidaskClub lowered shares of Maximus from a “hold” rating to a “sell” rating in a report on Monday, July 24th. KeyCorp reaffirmed a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. Finally, ValuEngine lowered shares of Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $62.17.
In other Maximus news, General Counsel David Francis sold 1,000 shares of the stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $63.14, for a total transaction of $63,140.00. Following the sale, the general counsel now owns 18,716 shares of the company’s stock, valued at approximately $1,181,728.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Andrekovich sold 8,939 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $64.01, for a total transaction of $572,185.39. Following the sale, the insider now directly owns 24,583 shares in the company, valued at approximately $1,573,557.83. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,636 shares of company stock worth $6,874,122. Insiders own 3.10% of the company’s stock.
Large investors have recently modified their holdings of the company. WCM Investment Management CA increased its position in Maximus by 7.5% in the first quarter. WCM Investment Management CA now owns 24,411 shares of the health services provider’s stock worth $1,518,000 after buying an additional 1,700 shares during the last quarter. Bank of Montreal Can increased its position in Maximus by 56.5% in the first quarter. Bank of Montreal Can now owns 125,084 shares of the health services provider’s stock worth $7,780,000 after buying an additional 45,167 shares during the last quarter. Capstone Asset Management Co. increased its position in Maximus by 3.0% in the first quarter. Capstone Asset Management Co. now owns 6,972 shares of the health services provider’s stock worth $434,000 after buying an additional 200 shares during the last quarter. Private Trust Co. NA acquired a new position in Maximus during the first quarter worth about $469,000. Finally, Louisiana State Employees Retirement System increased its position in Maximus by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 16,400 shares of the health services provider’s stock worth $1,020,000 after buying an additional 400 shares during the last quarter. 97.89% of the stock is currently owned by hedge funds and other institutional investors.
Maximus (NYSE:MMS) traded down 0.98% during mid-day trading on Tuesday, hitting $60.90. 407,776 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $61.60 and a 200 day moving average of $60.73. The stock has a market capitalization of $3.95 billion, a P/E ratio of 19.97 and a beta of 1.39. Maximus has a 52 week low of $43.69 and a 52 week high of $64.97.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, August 11th. Maximus’s dividend payout ratio is currently 5.73%.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.